Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
featured news
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Recently published open access in the Journal for ImmunoTherapy of Cancer (1), findings from a study led by VHIO’s Alena…
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with…
Molecular analysis of ductal carcinoma in situ (DCIS), the most common precursor of invasive breast cancer, has led to the…
VHIO takes part in this European project to expand tumour genome interpretation for personalised cancer treatment 21 – 23 November…
Published in ESMO Open, results of a phase I first-in-human study co-authored by investigators at the Vall d’Hebron Institute of…
